Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

Also called NCT03030235

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 324 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03030235
Main results
  • The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial Nature medicine, 2021-11 DOI, PubMed 34711976, PMC8604725 In the PMC Open Access subset under CC BY.
Other papers using this trial's data
  • Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF Circulation. Heart failure, 2023-11 DOI, PubMed 37869881, PMC10655911 In the PMC Open Access subset under CC BY-NC-ND.
  • Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial JACC. Heart failure, 2024-06 DOI, PubMed 38639697, PMC11153021 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03030235. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-01 (actual); primary completion 2021-08-13 (actual). Results posted on 2022-10-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
Acronym
PRESERVED-HF
Condition
Chronic Heart Failure With Preserved Systolic Function
Intervention (Drug)
Dapagliflozin 10Mg Oral Tablet
Intervention (Drug)
Dapagliflozin matching placebo
Lead sponsor
Saint Luke's Health System (class: other)

Record details

Record id
cardio:ct-nct03030235
Content hash
cfb070eb77b69668a79554ae1e399d476543f5256a9ef5d24420d2dc8e8b0ddb